Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 2078-T4

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
2078-T4-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

NS0

Accession #

AAH36827.1

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all LILRB2/CD85d/ILT4 Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human LILRB2/CD85d/ILT4 protein
Human LILRB2/CD85d/ILT4
(Gly24-His458)
Accession # AAH36827.1		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Gly24

Predicted Molecular Mass

73.9 kDa (monomer)

SDS-PAGE

94-100 kDa, reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human Angiopoietin-like Protein 5/ANGPTL5 (Catalog # 6675-AN) is coated at 4 μg/mL, Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera binds with a typical ED50 of 0.15-0.9 μg/mL.

Measured by its ability to support the adhesion of HSB2 human peripheral blood acute lymphoblastic leukemia cells.
Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera immobilized at 35 µg/mL, 100 µL/well, will mediate >40% HSB-2 cell adhesion (105 cells/well).

Scientific Data Images for Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF

Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein Binding Activity

Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein Binding Activity

Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (Catalog # 2078-T4) supports the adhesion of HSB2 human peripheral blood acute lymphoblastic leukemia cells. Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera immobilized at 35 µg/mL, 100 µL/well, will mediate >40% HSB-2 cell adhesion (105cells/well).

Formulation, Preparation and Storage

2078-T4
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 100 μg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: LILRB2/CD85d/ILT4

The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR) (1-3). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC) (4). Human ILT4 is produced as a 598 amino acid (aa) precursor including a 21 aa signal sequence, a 440 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 116 aa cytoplasmic domain. The ECD contains four Ig-like domains, and the cytoplasmic domain contains three immunoreceptor tyrosine-based inhibitory motifs (ITIM) (5). The ECD of human ILT4 shares 76% aa identity with chimpanzee ILT4 and 74%, 81%, 33%, 52%, 77%, 61%, and 64 % aa identity with human ILT1, 2, 3, 5, 6, 7, and 8, respectively. ILT4 binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules (5-9). It competes with CD8 alpha for MHC I binding but does not compete with KIR2DL1 (7). Ligation of ILT4 induces Tyr phosphorylation within its cytoplasmic ITIMs, a requirement for association with SHP-1 (4, 6). Activation of ILT4 inhibits signaling through Fc gamma RI (4) and Fc epsilon RI (6) and causes DC to become tolerogenic by down-regulation of co‑stimulatory molecules (10, 11). ILT4 mediates tolerogenic DC‑induced CD4+ T cell energy in vitro and in vivo (10-12).

References

  1. Suciu-Foca, N. et al. (2005) Int. Immunopharmacol. 5:7. 
  2. Hofmeister, V. and E.H. Weiss (2003) Semin. Canc. Biol. 13:317. 
  3. Hunt, J.S. et al. (2005) FASEB J. 19:681. 
  4. Finger, N.A. et al. (1998) Eur. J. Immunol. 28:3423. 
  5. Borges, L. et al. (1997) J. Immunol. 159:5192. 
  6. Colonna, M. et al. (1998) J. Immunol. 160:3096. 
  7. Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. 100:8856.
  8. Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552.
  9. Allen, R.L. et al. (2001) J. Immunol. 167:5543.
  10. Chang, C.C. et al. (2002) Nat. Immunol. 3:237.
  11. Ristich, V. et al. (2005) Eur. J. Immunol. 35:1133.
  12. Manavalan, J.S. et al. (2003) Transpl. Immunol. 11:245.

Long Name

Leukocyte Immunoglobulin-like Receptor, Subfamily B (with TM and ITIM Domains), Member 5

Alternate Names

CD85d, ILT4, LIR2, MIR10

Entrez Gene IDs

10288 (Human)

Gene Symbol

LILRB2

UniProt

AAH36827.1

Additional LILRB2/CD85d/ILT4 Products

Product Documents for Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.